Aytu biopharma reports fiscal 2024 third quarter operational and financial results

Q3 2024 adhd portfolio net revenue up 49% compared to q3 2023 q3 2024 adjusted ebitda 1 improved by $7.0 million compared to q3 2023 ttm march 2024 operating income of $7.3 million for the rx business ttm march 2024 companywide adjusted ebitda of positive $15.4 million ttm march 2024 adjusted ebitda of positive $17.1 million for the rx business $19.8 million cash balance at march 31, 2024 company to host conference call and webcast today, may 15, 2024, at 4:30 p.m. eastern time denver, co / accesswire / may 15, 2024 / aytu biopharma, inc. (the "company" or "aytu") (nasdaq:aytu), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 third quarter.
AYTU Ratings Summary
AYTU Quant Ranking